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Improved adherence adjustment in the
Coronary Drug Project
Eleanor J. Murray1* and Miguel A. Hernán1,2,3
Abstract
Background: The survival difference between adherers and non-adherers to placebo in the Coronary Drug Project
has been used to support the thesis that adherence adjustment in randomized trials is not generally possible and,
therefore, that only intention-to-treat analyses should be trusted. We previously demonstrated that adherence
adjustment can be validly conducted in the Coronary Drug Project using a simplistic approach. Here, we re-
analyze the data using an approach that takes full advantage of recent methodological developments.
Methods: We used inverse-probability weighted hazards models to estimate the 5-year survival and mortality
risk when individuals in the placebo arm of the Coronary Drug Project adhere to at least 80% of the drug
continuously or never during the 5-year follow-up period.
Results: Adjustment for post-randomization covariates resulted in 5-year mortality risk difference estimates
ranging from − 0.7 (95% confidence intervals (CI), − 12.2, 10.7) to 4.5 (95% CI, − 6.3, 15.3) percentage points.
Conclusions: Our analysis confirms that appropriate adjustment for post-randomization predictors of adherence largely
removes the association between adherence to placebo and mortality originally described in this trial.
Trial registration: ClinicalTrials.gov, Identifier: NCT00000482. Registered retrospectively on 27 October 1999.
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Background
In 1980, an analysis of the Coronary Drug Project (CDP)
randomized trial found a greater survival in individuals
who adhered to placebo than in those who did not
adhere to placebo [1]. Statistical adjustment for multiple
prognostic factors could not remove these survival
differences. This finding was used to support the thesis
that adherence adjustment in randomized trials is not
generally possible and, therefore, that only intention-to-
treat analyses should be trusted.
In 2016, we reported a re-analysis of the CDP placebo
arm that incorporated statistical advances not available in
1980. Our re-analysis showed that most of the survival
differences between placebo adherers and non-adherers
were actually removed after adjustment for pre- and post-
randomization prognostic factors [2]. Specifically, we modi-
fied the definition of adherence at missed visits, updated
the method of adjustment for baseline predictors of adher-
ence, and added adjustment for post-randomization predic-
tors of adherence via inverse-probability (IP) weighting.
With these changes, the 5-year survival difference
between placebo adherers and non-adherers decreased
from 10.9 percentage points (95% confidence interval,
7.5, 14.4) to 2.5 percentage points (95% confidence
interval, − 2.1, 7.0).
However, our re-analysis did not take full advantage of
the recent methodological advances. In an attempt to
conduct a re-analysis as comparable as possible to the
original 1980 analysis, we used a cumulative incidence
model that did not account for the exact time of death
during the 5-year period, and a somewhat unintuitive
measure of adherence – a binary indicator for cumulative
adherence greater than 80% during the entire 5-year
period. Although modeling the data this way was useful to
demonstrate that methods developed since 1980 can
address previously intractable sources of bias, the analytic
approach we used is not the recommended one. Here, we
demonstrate a better approach which uses a more natural
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definition of adherence and a survival analysis approach
to incorporate time of death.
A brief introduction to the Coronary Drug Project
The CDP was a six-arm double blind, placebo-controlled
randomized trial of 8341 men with a history of myocardial
infarction (MI) enrolled between 1966 and 1969 [3].
Eligibility criteria for participation in the trial included men
aged 30–64 years at entry, with an electrocardiogram-
documented MI at least 3 months prior to enrollment, a
New York Heart Association functional class of I (no limita-
tion in physical activity) or II (slight limitations only), no
prior surgery for coronary artery disease, no anti-coagulant
therapy or lipid-influencing therapy use at entry, and no
other chronic medical conditions which could affect trial
participation. In addition, potential participants were
required to complete a 2-month control period during
which all individuals were given placebo and only those who
adhered to at least 80% were eligible for randomization. Par-
ticipants were then randomized within study center and by
risk group (low risk if one prior MI with no complications;
high risk if more than one MI or complications).
Study medications were prescribed as three pills daily
at randomization, and dosage was increased to nine pills
daily, based on tolerance, over the following 2 months.
Adherence was assessed by study clinicians at each visit
based on a visual inspection of pill bottles, and recorded
as a six-level categorical variable (≥ 80%, 60–79%,
40–59%, 20–39%, 1–19%, none) which was then ad-
justed for expected dose at that visit [1, 2].
Three of the five active treatment arms were discon-
tinued early because of adverse events (low- and high-
dose equine estrogen, and dextrothyroxine) [4–6], and
the other two treatments (clofibrate and niacin) were
not found to be effective in reducing mortality [7]. The
5-year cumulative incidence of mortality was 20.9% in
the placebo arm, 20.0% in the clofibrate arm, and 21.2%
in the niacin arm [7].
Methods
We restricted our analyses to the 2787 men in the
placebo arm. Let t be an index for visit, where t = 0 is
the baseline visit and t = 14 is the last visit at year 5,
with 4-month intervals between each visit. Let At be an
indicator for adherence ≥ 80% to the protocol-specified
placebo dose between t and t + 1, Yt an indicator of
death between t and t + 1, Ct + 1 an indicator for loss to
follow-up defined as three consecutive missed study
visits at t + 1, V a set of 39 variables measured at the
time of randomization, and Lt a set of post-
randomization variables measured at each t. The base-
line covariates V were adherence during the run-in
period, demographics (age, race), lifestyle characteristics
(cigarette smoking, physical activity), medical history
(risk group, weight, New York Heart Association class,
comorbidities, blood pressure), use of non-study medica-
tions, laboratory findings, and electrocardiogram
findings. All of these variables (except age, race, weight,
risk group) were also post-randomization variables Lt at
each visit t. When an individual missed a study visit, the
most recent covariate and adherence values were carried
over from the most recent available data, up to three
consecutive missed visits. Participants were censored at
the expected date of their third consecutive missed
study visit.
The choice of 80% as a cut-point for adherence was
based on standard practice, as reflected by the use of a
run-in period requiring 80% adherence to placebo among
all trial participants. Note that, since adherence was
assessed as a categorical variable, with the highest category
≥ 80% of prescribed pills taken, higher thresholds were not
possible for the binary adherence indicator.
In our primary analysis, we artificially censored individ-
uals when they reported an adherence level that differed
from their baseline adherence level, that is, when At≠ A0
[8, 9]. We then fit the IP-weighted pooled logistic model
for the discrete-time hazards at each time [10]:
logitðPr½Y tþ1 ¼ 1j Ak ¼ A0 for 0 < k ≤ t;V ;
Ctþ1 ¼ 0;Y t ¼ 0 Þ
¼ θ0;t þ θ1A0 þ θ2V þ θ3A0t;
where θ0,t is a time-varying intercept modeled as a re-
stricted cubic spline of time (knots at 0, 5, 10, 15 visits),
and θ2 is a vector parameter. The time-varying stabilized




f ðMk ;Ak jA0;Āk−1;V ;Ck ¼ 0Þ
f Mk ;Ak jA0;Āk−1;V ; Lk ;Ck ¼ 0
 
;
where Mt is an indicator for measurement of adherence
at visit t (1 if measured, 0 otherwise), and overbars indi-
cate history of the variable. The weight models were fit
in the full population before artificial censoring; in a sen-
sitivity analysis, we restricted the fit of the weight
models to person-visits with Ak= A0 for 0 < k ≤ t.
To estimate the denominator of the weights, we fit the
model logit(Pr[Mt = 1|A0;Āt−1;V ; Lt ;Ct ¼ 0 ]) = α0t +
α1A0 + α2At − 1 + α3V + α4Lt − 1 to all person-visits, and
the model logit(Pr[At = 0|A0;Āt−1;V ; Lt ;Ct ¼ 0,Mt = 1])
= β0t + β1A0 + β2At − 1 + β3V + β4Lt to the person-visits
with measured adherence. When adherence was not
measured at a visit (Mt = 0) but the individual was not
yet defined to be lost to follow-up (that is, at the first or
second consecutive missed visit), adherence was carried
forward from the previous visit and the factor in the de-
nominator of the adherence weight was 1 for that visit.
Similar models that did not include the time-varying
covariates were fit to estimate the numerators of the
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weights. The final weight for each individual at each
time was the product of the measurement and adher-
ence weights for that individual up to that time point.
As in previous studies, we truncated the estimated IP
weights at the 99th percentile to avoid undue influence
of outliers. The truncated weight estimates had a mean
of 1.00 (SD = 0.29) and a range of 0.02 to 2.55.
We used the parameter estimates from the weighted out-
come logistic model to estimate the 5-year survival as pre-
viously described [2]. We compared the survival for always
vs. never at least 80% adherent, that is, A0 = 0 vs. A0 = 1.
We conducted a second analysis where, rather than
censor individuals who reported a change in adherence,
we specified a dose-response function for the effect of
adherence on mortality. To do so, we summarized the
adherence history Āt between baseline and visit t by the
cumulative average cum(Āt) = 1tþ1
Pt
k¼0 Ak (i.e., the pro-
portion of visits during which an individual was adher-
ent to at least 80% of the placebo dose), and then fit the
pooled logistic model
logitð Pr½Y tþ1 ¼ 1jĀt ;V ;Ctþ1 ¼ 0;Y t ¼ 0 Þ
¼ θ0;t þ θ1 f cum Ātð Þ½  þ θ2V ;
where f[·] is a dose-response function and θ1 is a vector
parameter.
In separate analyses, we specified more flexible dose-
response functions. Specifically, we considered both a
quadratic dose-response function θ1f[cum(Āt)] =
θ1,1cum(Āt) + θ1,2[cum(Āt)]
2, and a function that
allowed for a separate effect of recent adherence θ1,0At
+ θ1,1cum(Āt - 1) + θ1,2[cum(Āt - 1)]
2. We also consid-
ered functions that included product terms with the
time parameters.
To compute 95% confidence intervals, we used non-
parametric bootstrapping with 500 samples.
SAS 9.4 was used for all analyses and code is
provided in the supplementary online materials (see
Additional file 1).
Results
Using our primary hazards models with artificial censoring,
the estimated 5-year mortality risk difference between
adherers and non-adherers in the placebo arm was 0.01
percentage points (95% confidence interval, -12.2, 13.2)
after adjusting for post-randomization covariates (Table 1).
Estimates based on dose-response hazards models without
artificial censoring gave consistent estimates ranging from
less than 1 percentage point to approximately 5 percentage
points. Using an oversimplified dose-response model (a
linear term only for cumulative adherence) resulted in
implausible risk estimates (data not shown). The results
were robust to other modeling choices, such as the number
or placement of knots for the spline of time. As a sensitivity
analysis, we also assessed censoring individuals for loss to
follow-up at the second missed visit. Results were similar
with an estimated 5-year mortality risk difference of 8.8
percentage points (95% CI, − 1.7, 20.7) in the unadjusted
analysis and 0.6 percentage points (95% CI, − 8.1, 10.5) after
adjusting for post-randomization covariates. When we
restricted the fit of the weight models to person-visits with
Ak= A0 for 0 < k ≤ t, the 5-year mortality risk difference ad-
justed for post-randomization covariates increased slightly
to 3.1 percentage points (95% CI, − 3.1, 9.4).
Discussion
Our analysis confirms that the survival differences between
adherers and non-adherers to placebo can be largely
adjusted away in the Coronary Drug Project. Adjustment
for post-randomization predictors of adherence results in
estimated 5-year mortality risk differences comparing
adherence and non-adherence to placebo that are approxi-
mately null regardless of the analytic approach used. Our
previous analysis [2] reached a similar conclusion but, by
simply estimating the cumulative mortality at the end of
follow-up, ignored the timing of events. In contrast, the
current analyses use a survival analysis approach that allows
estimation of adjusted survival curves for adherers and
non-adherers throughout the follow-up.
Table 1 Estimated difference in 5-year mortality risk (95% confidence interval) when comparing 0% vs. 100% of follow-up being at
least 80% adherent, Coronary Drug Project
Method Unadjusted Standardized by baseline
covariates
+ IP weighting for post-
randomization covariates
Censoring when binary adherence level deviates from baseline 9.6 (– 7.0, 28.9) 1.5 (– 11.0, 16.4) 0.01 (– 12.2, 13.2)
Dose-response hazards models
Quadratic cumulative adherence 6.7 (− 3.2, 16.5) 2.6 (− 5.8, 11.1) 0.2 (− 8.2, 8.6)
Quadratic cumulative adherence, with time interaction 6.0 (− 5.8, 18.0) 1.6 (− 8.4, 11.6) − 0.7 (− 12.2, 10.7)
Binary current adherence, plus quadratic cumulative
adherence up to previous visit
11.6 (− 1.0, 24.2) 6.4 (− 3.9, 16.8) 4.5 (− 6.3, 15.3)
Binary current adherence, plus quadratic cumulative
adherence up to previous visit, with time interaction
10.3 (− 2.3, 22.9) 4.0 (− 6.0, 14.1) 2.4 (− 9.3, 14.1)
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We used two methods to compare the survival under
continuous high-average adherence vs. low adherence
(< 80%). The first method was a relatively inefficient
censoring procedure that does not require a dose-
response model for the effect of cumulative adherence
on mortality. The second method was a theoretically
more efficient method that requires a dose-response
model and, therefore, will result in bias if the dose-
response model is misspecified. We considered a variety
of dose-response functions, which made different assump-
tions about the relationship between adherence and mor-
tality over time. When sufficient data are available, more
flexible dose-response functions are generally preferable
as they impose fewer a priori constraints. For example, a
function that models separately current adherence and
prior cumulative adherence (using, say, linear and quad-
ratic terms as in our analysis) requires fewer assumptions
than a function that models total cumulative adherence.
However, the added flexibility comes at the price of less
precise estimates. Unlike in other examples [12], our esti-
mates were not very sensitive to the choice of dose-
response model. Further research into dose-response
modeling for adherence-adjusted estimates is warranted.
Obtaining a null estimate when comparing adherers and
non-adherers in the placebo arm supports the validity of
adherence-adjusted effect estimates in randomized trials.
However, this comparison relies on the lack of psychobio-
logical effects of placebo on mortality. For other out-
comes, such as pain or symptom severity, this assumption
may be less reasonable.
Conclusion
Adherence-adjusted analyses of randomized controlled tri-
als have been viewed with some skepticism with some au-
thors suggesting that adherence is intractably confounded
[1]. However, we have demonstrated that adjustment for
post-randomization predictors of adherence can create
comparability between adherers and non-adherers when
rich data on pre-and post-randomization confounders exist.
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